Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1

BACKGROUND: Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and other new drugs are revolutionizing its treatment. It remains unclear why myelomas are peculiarly sensitive to bortezomib, or what...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ling, Silvia C. W., Lau, Edwin K. K., Al-Shabeeb, Ammira, Nikolic, Angela, Catalano, Albert, Iland, Harry, Horvath, Noemi, Ho, P. Joy, Harrison, Simon, Fleming, Shaun, Joshua, Douglas E., Allen, John D.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ferrata Storti Foundation 2012
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3248932/
https://ncbi.nlm.nih.gov/pubmed/21993678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.043331
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg